We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 212

Allegations as to non-infringement of Form I held to be justified

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 23 2014

Teva asserted both non-infringement and invalidity in its Notice of Allegation. The Court noted that invalidity of this patent had been before it

Fact-specific issues relevant to calculating section 8 damages are decided

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • December 18 2013

This decision provides answers to certain issues that would allow the parties to calculate the loss under section 8 of thePM(NOC) Regulations that

Other industry news

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • October 28 2013

Health Canada has released of the Therapeutic Products Directorate Statistical Report 20122013 for the Patented Medicines (Notice of Compliance

Teva's allegation for section 8 damages not struck on appeal

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • October 28 2013

Pfizer appealed a decision refusing to strike Teva’s Statement of Claim to the Federal Court, but the appeal was dismissed because a de novo review

Order of prohibition granted in respect of one of two asserted patents

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • October 28 2013

Two patents were under consideration by the Court in this application brought pursuant to the Patented Medicines (Notice of Compliance) Regulations

Intellectual property weekly abstracts bulletin

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 17 2013

Although the Court of Appeal had split 2-1, the Supreme Court refused Takeda's application for leave as well as the motion to intervene by Canada's

Teva Canada Innovation v. Attorney General of Canada

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 8 2013

The Patented Medicine Prices Review Board (the PMPRB) ordered Teva to pay the Crown approximately $2.4 million for selling its product at an

Intellectual property weekly abstracts bulletin

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 1 2013

The Court granted a Prohibition Order to AstraZeneca, preventing Ranbaxy from entering the market with a generic version of ompeprazole until the

Leave to appeal to the Court of Appeal Re: motion to strike pleadings granted in respect of claims to unjust enrichment, denied in respect of claims under the Trade-Marks Act

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 6 2013

In this case, Apotex has sued Eli Lilly for damages pursuant to s. 8 of the Patented Medicines (Notice of Compliance) Regulations. Eli Lilly brought a

Other industry news

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 27 2013

Health Canada has released a Draft (Step 2) International Conference on Harmonisation of Technical Requirements for the Registration of